Practical Application of Artificial Intelligence in Drug Discovery and Development
Valuation of Your Early Drug Candidate
Successful Biotech Licensing Negotiations
A Medical Device Manufacturer's Guide to Selecting Suppliers
This white paper covers when to consider using suppliers, key differences between standard / OTS and custom part suppliers, tools and methods for managing suppliers, and when and how to transition between suppliers and internal resources.
Getting Ready for a Biopharma Partnering Deal
How to Apply the Golden Rule of Research to your Trial Master File
This whitepaper evaluates the regulations that support GDP, best practices on how document contributors can apply the golden rule of research to their TMF, how to avoid writing too many and unnecessary Note-to-Files (NTFs), and tips on becoming inspection ready and staying that way.
Demystifying Tech M&A Valuation
Selling Your Healthcare or Life Sciences Company
This whitepaper gives medical groups, life sciences, and healthcare companies in the lower middle market an understanding of financing and M&A alternatives available, the role of financial buyers, key issues around selling equity in your business, and the typical financing and M&A process.
Pullan's Pieces - A Business Development View of the Oncology Landscape
In this whitepaper, biopharma partnering expert and Life Sciences consultant, Linda Pullan, PhD, explores the current oncology landscape and offers insightful perspective on trends, pipeline by indication, dealmaking, and the top ten oncology companies and the drugs they’re developing.
The Nuts & Bolts of Due Diligence in Biopharma Partnering
What's Hot and What's Not in Oncology Licensing in 2020?
How to Win at the Partnering Game
In this white paper, Linda Pullan provides a review of the rules of the partnering game – whether it’s partnering from preclinical to late clinical development – to provide an understanding of what to expect in moving from introductions to negotiations of a license or acquisition and how to win with a clear strategy.